Contact this trialFirst, we need to learn more about you.
Epigenetic Modifier
Pembrolizumab + Epigenetic Drugs for Lung Cancer
Recruiting1 awardPhase 1
Baltimore, Maryland
This trial is testing the safety of combining three drugs to treat cancer. Pembrolizumab will be given at a set dose, while guadecitabine and mocetinostat will be given at different doses to test their efficacy and side effects.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.